IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin

被引:2
|
作者
Osinusi, Anu [1 ,2 ]
Chary, Aarthi [3 ,4 ]
Winters, Mark A. [3 ,4 ]
Naggie, Susanna [5 ]
Masur, Henry [6 ]
Polis, Michael A. [2 ]
Kottilil, Shyam [2 ]
Holodniy, Mark [3 ,4 ]
机构
[1] NCI, CMRP, SAIC Frederick Inc, Frederick, MD 21701 USA
[2] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
[3] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA
[4] Stanford Univ, Stanford, CA 94305 USA
[5] Duke Clin Res Inst, Durham, NC USA
[6] NIH, Dept Crit Care Med, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
HIV; HCV; IL28B; HCV protease diversity; genomics; HUMAN-IMMUNODEFICIENCY-VIRUS; QUASI-SPECIES DIVERSITY; CHRONIC HEPATITIS-C; THERAPY; PEGINTERFERON; BOCEPREVIR; TELAPREVIR; COINFECTION; GENOTYPE-1; RESPONSES;
D O I
10.1002/jmv.23376
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Recent studies have demonstrated that IL28B polymorphisms predict therapeutic responses in chronic hepatitis C virus (HCV)-treated patients; however, the effect on HCV viral diversity, particularly on the HCV protease gene, is not clear. This study sought to evaluate the effect of IL28B polymorphisms on HCV diversity at NS3/4 protease region, which may influence therapeutic response to an HCV protease inhibitor based regimen. Twenty-two patients co-infected with HIV and HCV genotype 1, treatment-naive on stable HIV antiretroviral therapy initiating interferon-based treatment were evaluated. Plasma HCV NS3 gene diversity was analyzed by clonal analysis at baseline and end of treatment. IL28B (rs12979860) genotypes were tested for associations with virologic outcomes and diversity parameters. There was similar baseline NS3 diversity in patients with CC (favorable) genotype compared to those with CT/TT (unfavorable) genotypes. There was no significant association between IL28B genotype and baseline NS3 nucleotide p-distance, dS-dN, amino acid p-distance, or nucleotide changes. Among patients without a sustained virologic response, between baseline and follow-up there was a significant trend towards decreased diversity after treatment among patients with favorable genotype, which was not observed in unfavorable genotypes. In patients treated with peginterferon/ribavirin therapy, IL28B polymorphism was not associated with enhanced NS3 diversity at baseline. Among non-SVR patients with the less favorable genotype, there was no change in diversity after treatment. This suggests that IL28B genotype is unlikely to have a negative impact on subsequent HCV PI efficacy in patients co-infected with HIV and HCV patients who have previously failed HCV therapy. J. Med. Virol. 84:15221527, 2012. (c) Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
引用
收藏
页码:1522 / 1527
页数:6
相关论文
共 50 条
  • [21] Growth factors versus dose reduction for pegylated interferon alfa-2b and ribavirin associated neutropenia and anemia in HIV/HCV co-infected patients
    Kadam, Jaydeep S.
    Jones, Kristina
    Peterson, Ray
    Dove, Loren
    Pearce, Daniel
    Hassanein, Tarek
    Doonquah, Leeleka
    Glesby, Marshal
    Heller, Larry
    Aboulafia, David
    Rodriguez, Jorge
    Bonilla, Hector
    Galpin, Jeff
    Aberg, Judy
    Johnston, Barbara
    Liu, Ray
    Jacobson, Ira M.
    Talal, Andrew H.
    GASTROENTEROLOGY, 2006, 130 (04) : A838 - A839
  • [22] HCV treatment with pegylated interferon and ribavirin in patients with haemophilia and HIV/HCV co-infection
    Denholm, J. T.
    Wright, E. J.
    Street, A.
    Sasadeusz, J. J.
    HAEMOPHILIA, 2009, 15 (02) : 538 - 543
  • [23] Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients
    Merchante, Nicolas
    de los Santos-Gil, Ignacio
    Merino, Dolores
    Gonzalez-Serrano, Mercedes
    Mira, Jose A.
    Sanz-Sanz, Jesus
    Fernandez-Fuertes, Elisa
    Ruiz-Morales, Josefa
    del Valle, Jose
    Macias, Juan
    Moro, Antonio
    Pineda, Juan A.
    JOURNAL OF HEPATOLOGY, 2009, 50 (04) : 684 - 692
  • [24] IL23 PROMOTES INTERFERON RESPONSIVENESS IN HIV/HCV COINFECTED PATIENTS TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN
    Odigie, Madeline
    Zhang, Xiaozhen
    Masur, Henry
    Polis, Michael A.
    Kottilil, Shyam
    Osinusi, Anu
    HEPATOLOGY, 2011, 54 : 488A - 488A
  • [25] Influence of IL28B gene polymorphisms on PegINF-RBV-mediated HCV clearance in HIV-HCV co-infected patients: A meta-analysis
    Kumar, Nirmal
    Prabhu, Suchitra S.
    Monga, Isha
    Banerjee, Indranil
    META GENE, 2021, 29
  • [26] The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients
    Nattermann, J.
    Bueren, K.
    Nischalke, H. D.
    Ahlenstiel, G.
    Berg, T.
    Biermer, M.
    Sauerbruch, T.
    Vogel, M.
    Rockstroh, J. K.
    Spengler, U.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S235 - S236
  • [27] Therapeutical aspects and predictors of outcome for HIV/HCV co-infected patients treated with pegylated interferon plus ribavirin. Survey in an Italian university hospital
    Righi, E.
    Bassetti, M.
    Di Biagio, A.
    Dentone, C.
    Rosso, R.
    Beltrame, A.
    Mazzarello, G.
    Ratto, S.
    Viscoli, C.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S543 - S543
  • [28] RAPID VIROLOGIC RESPONSE (RVR), IL28B SINGLE NUCLEOTIDE POLYMORPHISM (SNP) RS12980275 AND HCV GENOTYPE ARE INDEPENDENT PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE (SVR) IN HIV/HCV COINFECTED PATIENTS TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN
    Puoti, Massimo
    Covolo, Loredana
    Nasta, Paola
    Gatti, Francesca
    Suter, Fredy
    Mussini, Cristina
    Bruno, Raffaele
    Ferrari, Carlo
    Santantonio, Teresa
    Di Marco, Vito
    Craxi, Antonio
    HEPATOLOGY, 2011, 54 : 873A - 874A
  • [29] IL28B SNP rs8099917 Is Strongly Associated with Pegylated Interferon-α and Ribavirin Therapy Treatment Failure in HCV/HIV-1 Coinfected Patients
    Aparicio, Ester
    Parera, Mariona
    Franco, Sandra
    Perez-Alvarez, Nuria
    Tural, Cristina
    Clotet, Bonaventura
    Angel Martinez, Miguel
    PLOS ONE, 2010, 5 (10):
  • [30] IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV-HIV-1-coinfected patients
    Aparcio, E.
    Parera, M.
    Franco, S.
    Perez-Alvarez, N.
    Tural, C.
    Clotet, B.
    Martinez, M. A.
    ANTIVIRAL THERAPY, 2010, 15 : A119 - A119